Remove Immunization Remove Labelling Remove Vaccines
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.

Vaccines 134
article thumbnail

EMA panel probes heart inflammation with Pfizer/BioNTech COVID vaccine

pharmaphorum

A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot. . It is also asking for similar data from Moderna, which manufacture a COVID-19 vaccine that like Comirnaty is based on mRNA.

Vaccines 122
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How advanced technology can streamline the COVID-19 vaccine rollout

pharmaphorum

Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.

Vaccines 119
article thumbnail

Merck raises pressure on Pfizer in pneumococcal vaccine tussle

pharmaphorum

Just a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has reported positive trial results in children that will ramp up the pressure on Pfizer and its market-leading Prevnar franchise.

Vaccines 105
article thumbnail

E.U. Regulator Argues to Continue J&J Vaccine With a Warning Label

NY Times

The European Union’s drug regulator said that the Johnson and Johnson vaccine should carry a warning of potential risk for rare blood clots on the label, but did not recommend stopping the vaccine, saying the benefits of the vaccine outweighed the risks.

article thumbnail

Moderna’s mRNA vaccine along with Keytruda obtains PRIME designation

Pharmaceutical Technology

Moderna has announced that its cancer vaccine mRNA-4157/V940 along with Keytruda secured the European Medicines Agency (EMA) Priority Medicines (PRIME) scheme designation for the adjuvant treatment of high-risk stage III/IV melanoma patients after complete resection.

article thumbnail

UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine

Big Molecule Watch

On February 5, 2025 Valneva SE (Valneva) announced that the United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Valnevas chikungunya vaccine, IXCHIQ. The post UKs MHRA Grants Marketing Authorization for Chikungunya Vaccine appeared first on Big Molecule Watch.